The impact of different strategies to handle missing data on both precision and bias in a drug safety study: a multidatabase multinational population-based cohort study by Martin-Merino, E, Calderón-Larrañaga, A, Hawley, S, Poblador-Plou, B, Llorente, A, Petersen, I, Prieto-Alhambra, D

“…<strong>Methods:</strong> New users of AOM (alendronic acid, other bisphosphonates, strontium ranelate, selective estrogen receptor modulators, teriparatide, or denosumab) aged ≥50 years during 1998–2014 were identified in two Spanish (the Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria [BIFAP] and EpiChron cohort) and one UK (Clinical Practice Research Datalink [CPRD]) EMR. …”

Secular trends of use of anti-osteoporosis treatments in Spain: a population-based cohort study including over 1.5 million people and more than 12 years of follow-up by Martín-Merino, E, Huerta-Álvarez, C, Prieto-Alhambra, D, Álvarez-Gutiérrez, A, Montero-Corominas, C

“…Participants entered the study when aged ≥50 years in 2001-2013 and after 1 year of data available, and were followed to an AOM prescription (including alendronate, other bisphosphonates, SERM (selective estrogen receptor modulators), strontium ranelate, teriparatide or denosumab), death, lost or the end of December 2013. …”

Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on “real-world” data: a meta-analysis of propensity-matched cohort findings from the UK... by Khalid, S, Calderon-Larrañaga, S, Hawley, S, Ali, M, Judge, A, Arden, N, Van Staa, T, Cooper, C, Javaid, M, Prieto-Alhambra, D

“…Users of alendronate (reference group) were compared to those of (1) OBP, (2) strontium ranelate (SR), and (3) selective estrogen receptor modulators (SERMs), after matching on baseline characteristics using propensity scores. …”